Oral supplementation with cholecalciferol 800 IU ameliorates albuminuria in Chinese type 2 diabetic patients with nephropathy

PLoS One. 2012;7(11):e50510. doi: 10.1371/journal.pone.0050510. Epub 2012 Nov 29.

Abstract

Background: Low vitamin D levels can be associated with albuminuria, and vitamin D analogs are effective anti-proteinuric agents. The aim of this study was to investigate differences in vitamin D levels between those with micro- and those with macroalbuminuria, and to determine whether low dose cholecalciferol increases vitamin D levels and ameliorates albuminuria.

Methods: Two studies were performed in which 25-OH vitamin D(3) (25(OH)D(3)) concentrations were determined by electrochemiluminescence immunoassay: 1) a cross-sectional study of patients with type 2 diabetes mellitus (T2DM) (n = 481) and healthy controls (n = 78); and 2) a longitudinal study of T2DM patients with albuminuria treated with conventional doses, 800 IU, of cholecalciferol for 6 months (n = 22), and a control group (n = 24).

Results: 1) Cross-sectional study: Compared to controls and T2DM patients with normoalbuminuria, serum 25(OH)D(3) concentrations were significantly lower in patients with macro-albuminuria, but not in those with micro-albuminuria. Serum 25(OH)D(3) levels were independently correlated with microalbuminuria. 2) Longitudinal study: Cholecalciferol significantly decreased microalbuminuria in the early stages of treatment, in conjunction with an increase in serum 25(OH)D(3) levels.

Conclusions: Low vitamin D levels are common in type 2 diabetic patients with albuminuria, particularly in patients with macroalbuminuria, but not in those with microalbuminuria. Conventional doses of cholecalciferol may have antiproteinuric effects on Chinese type 2 diabetic patients with nephropathy.

Publication types

  • Clinical Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Administration, Oral
  • Adult
  • Albuminuria / drug therapy*
  • Albuminuria / metabolism
  • Cholecalciferol / administration & dosage*
  • Cholecalciferol / therapeutic use*
  • Cross-Sectional Studies
  • Diabetes Mellitus, Type 2 / drug therapy*
  • Diabetic Nephropathies / drug therapy*
  • Diabetic Nephropathies / metabolism
  • Female
  • Humans
  • Longitudinal Studies
  • Male
  • Middle Aged

Substances

  • Cholecalciferol

Grants and funding

This work was supported by Major State Basic Research Development Program of China (973 program) No.2012CB517700 to H. Chen, the grants of National Natural Science Foundation of China No.81070649 to H. Chen, the Program for New Century Excellent Talents in University to H. Chen, and the projects of Shanghai Municipal Health Bureau No.20114323 to H. Yu. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.